Tweet
November 9, 2022
doi:10.1001/jamanetworkopen.2022.41144
Rohan Khazanchi, MD, MPH1,2,3; Andrew Strumpf, MPH4; Utibe R. Essien, MD, MPH5,6; et al
Introduction
Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19.1 Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free.2 However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.3-5 To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
doi:10.1001/jamanetworkopen.2022.41144
Rohan Khazanchi, MD, MPH1,2,3; Andrew Strumpf, MPH4; Utibe R. Essien, MD, MPH5,6; et al
Introduction
Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19.1 Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free.2 However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.3-5 To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
